Maze Therapeutics, Inc. (NASDAQ:MAZE - Get Free Report) has received a consensus rating of "Buy" from the six research firms that are covering the company, MarketBeat reports. Four research analysts have rated the stock with a buy recommendation and two have given a strong buy recommendation to the company. The average 1-year price target among brokers that have issued a report on the stock in the last year is $23.50.
MAZE has been the subject of several analyst reports. Wedbush initiated coverage on Maze Therapeutics in a report on Tuesday. They issued an "outperform" rating and a $17.00 price target for the company. Guggenheim restated a "buy" rating and set a $19.00 price objective on shares of Maze Therapeutics in a report on Wednesday, April 2nd.
Read Our Latest Report on MAZE
Maze Therapeutics Price Performance
Shares of Maze Therapeutics stock traded up $1.23 during trading on Tuesday, hitting $13.35. 12,580 shares of the company were exchanged, compared to its average volume of 211,263. Maze Therapeutics has a fifty-two week low of $6.71 and a fifty-two week high of $17.00. The stock has a 50 day moving average of $11.22.
Maze Therapeutics (NASDAQ:MAZE - Get Free Report) last issued its quarterly earnings data on Wednesday, May 14th. The company reported ($1.15) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.76) by ($0.39).
Institutional Trading of Maze Therapeutics
Institutional investors have recently added to or reduced their stakes in the business. General Catalyst Group Management LLC purchased a new stake in Maze Therapeutics during the 1st quarter worth $11,405,000. Bessemer Group Inc. purchased a new stake in Maze Therapeutics during the 1st quarter worth $5,305,000. Hhlr Advisors LTD. purchased a new position in Maze Therapeutics in the 1st quarter valued at about $5,037,000. Driehaus Capital Management LLC purchased a new position in Maze Therapeutics in the 1st quarter valued at about $1,455,000. Finally, Ghisallo Capital Management LLC purchased a new position in Maze Therapeutics in the 1st quarter valued at about $330,000.
About Maze Therapeutics
(
Get Free ReportWe are a clinical-stage biopharmaceutical company harnessing the power of human genetics to develop novel, small molecule precision medicines for patients living with renal, cardiovascular and related metabolic diseases, including obesity. We are advancing a pipeline using our Compass platform, which allows us to identify and characterize genetic variants in disease and then link those variants to the biological pathways that drive disease in specific patient groups through a process we refer to as variant functionalization.
Featured Articles
This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.
Before you consider Maze Therapeutics, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Maze Therapeutics wasn't on the list.
While Maze Therapeutics currently has a Buy rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Market downturns give many investors pause, and for good reason. Wondering how to offset this risk? Enter your email address to learn more about using beta to protect your portfolio.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
